Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Themis

- PMLiVE

MSD to create strong UK discovery centre in London

The pharma group aims to start operations by 2020

- PMLiVE

CHMP backs MSD’s CMV infection treatment

Prevymis is set to be available as an injectable and tablets

- PMLiVE

Merck pulls Keytruda filing in Europe, despite US approval

Phase II KeyNote-0241 trial results failed to win over the EMA

Eli Lilly HQ

Lilly expands its immuno-oncology work with $1.8bn CureVac deal

Will work with the German firm to develop ‘next generation’ cancer vaccines

- PMLiVE

MSD touts Keytruda first-line promise in NSCLC

Says patients on the drug more than doubled median OS compared to chemo

Sanofi reception

Sanofi earmarks €170m for new French vaccines facility

Will expand its Val de Reuil production unit

- PMLiVE

MSD’s Keytruda wins new bladder cancer indication in Europe

Will treat locally advanced or mUC patients

- PMLiVE

Merck CEO resigns from Trump post in Charlottesville protest

Frazier leaves the Manufacturing Council but J&J’s Gorksy remains for now

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

IMI aims €130m at medical research’s unanswered questions

Targets for the partnership’s latest funding round including Alzheimer’s

- PMLiVE

Merck suspends two Keytruda trials after patient deaths

Investigators to look at Keytruda with Pomalyst and Revlimid

- PMLiVE

MSD probed by UK for blocking Remicade biosimilars

Pharma giant’s discount scheme for infliximab labelled ‘anti-competitive’

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links